Branched-chain-amino-acid transaminase 2 (BCAT2), also called branched-chain-amino-acid aminotransferase, mitochondrial (BCATM), is an enzyme that in humans is encoded by the gene BCAT2. This enzyme participates in the first step in breaking down the branched-chain amino acids: leucine, isoleucine, and valine. It differs from BCAT1, the other form of branched-chain amino acid aminotransferase (EC 2.6.1.42) found in humans, by being in the mitochondria instead of the cytoplasm.
This enzyme catalyzes the following catabolism reactions (EC 2.6.1.42):
using pyridoxal 5'-phosphate (active vitamin B6) as a cofactor.
Pathogenic mutations in BCAT2 are associated with high levels of branched chain amino acids in the blood, a condition called hypervalinemia and hyperleucine-isoleucinemia (HVLI) or branched-chain aminotransferase deficiency. Symptoms are heterogeneous and relatively mild compared to maple syrup urine disease. Symptoms have included headaches and (mild) memory impairment. This disorder is inherited in an autosomal recessive manner and has had only eight cases reported in the research literature as of 2025.
BCAT2 also acts as a (HLA-I-type) minor histocompatibility antigen, which are proteins that impact the rate of tissue and organ transplant rejection. In particular, this is associated with the genetic variant rs11548193/LB-BCAT2-1R.